1. Home
  2. Author: BioFactura

All posts by: BioFactura

About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.

BioFactura announces initiation of Phase I study of BFI-751, a Stelara® (ustekinumab) biosimilar

Frederick, Maryland, May 25, 2021: BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first … Continue reading

May 25, 2021 Press Releases

BioFactura Funded $13 Million Contract Option for its Smallpox Biodefense Therapeutic

Frederick, Maryland, February 19, 2021:  BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract valued at … Continue reading

February 19, 2021 Press Releases

BioFactura Granted New US AND European Patent for Its StableFast Biomanfacturing Platform

Frederick, Maryland, September 24, 2020: BioFactura, Inc. was issued a new patent in the U.S. and also granted patent coverage in the EU for novel technologies that improve the productivity of its proprietary StableFastTM Biomanufacturing Platform.  The new Multiplex Selection components of the platform allow for concurrent selection strategies to be applied during stable cell … Continue reading

September 24, 2020 Press Releases

BioFactura Awarded $1 Million SBIR Contract for Development of a Marburg Virus Therapeutic

Frederick, Maryland, July 27, 2020: BioFactura, Inc. today announced a $1 million Small Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD).  The goal of this project is to develop, optimize, and scale-up a highly efficient mammalian cell culture-based … Continue reading

July 27, 2020 Press Releases

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic

Frederick, Maryland, September 26, 2019:  BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment of smallpox.  This product has the potential to fulfill an … Continue reading

September 26, 2019 Press Releases

University of Vermont Health Network Ventures and Wilson Sonsini Goodrich & Rosati Invest in BioFactura

Frederick, Maryland, April 29, 2019:  The University of Vermont Health Network Ventures and legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round. “With the commitment from the UVM fund and WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and business resources to bear as … Continue reading

April 29, 2019 Press Releases

Intranasal monkeypox marmoset model: Prophylactic antibody treatment provides benefit against severe monkeypox virus disease

Eric M. Mucker, Suzanne E. Wollen-Roberts, Adrienne Kimmel, Josh Shamblin, Darryl Sampey and Jay W. Hooper. PLOS Neglected Tropical Diseases.  June 2018. Concerns regarding outbreaks of human monkeypox or the potential reintroduction of smallpox into an immunological naïve population have prompted the development of animal models and countermeasures. Here we present a marmoset model of monkeypox and smallpox disease utilizing a … Continue reading

June 23, 2018 Publications

At The Crossroads of Innovation and Commercialization Dr. Jeffrey Hausfeld Alters the Healthcare and Life Sciences Landscape

Washington D.C, 29th April 2018 Dr. Jeffrey Hausfeld M.D., M.B.A., F.A.C.S, chairman and co-founder of the global biomedical and healthcare innovation network, Society of Physician Entrepreneurs (www.sopenet.org), partners with and attends the The 15th Annual World Health Care Congress in Washington D.C. from April 29th – May 2nd, 2018. He will be co–moderating the inaugural … Continue reading

April 29, 2018 In The News